Thirty- Day Mortality Risk Associated With the Postoperative Nonresumption of Angiotensin-Converting Enzyme Inhibitors: A Retrospective Study of the Veterans Affairs Healthcare System

被引:44
作者
Mudumbai, Seshadri C. [1 ,2 ]
Takemoto, Steven [3 ,4 ]
Cason, Brian A. [3 ,4 ]
Au, Selwyn [5 ]
Upadhyay, Anjali [6 ]
Wallace, Arthur W. [3 ,4 ]
机构
[1] Vet Affairs Palo Alto Hlth Care Syst, Anesthesia Serv, Palo Alto, CA USA
[2] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA
[3] Vet Affairs Med Ctr, Anesthesia Serv, San Francisco, CA 94121 USA
[4] Univ Calif San Francisco, Dept Anesthesiol & Perioperat Care, San Francisco, CA 94143 USA
[5] Vet Affairs Palo Alto Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, Palo Alto, CA USA
[6] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Palo Alto, CA USA
关键词
BETA-BLOCKER WITHDRAWAL; DISCONTINUATION; MEDICATION; THERAPY; GUIDELINES; MANAGEMENT; SURGERY; CONSEQUENCES; POLYPHARMACY; EVENTS;
D O I
10.1002/jhm.2182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUNDAngiotensin-converting enzyme inhibitors (ACE-Is) are a widely used class of cardiovascular medication. However, limited data exist on the risks of postoperative nonresumption of an ACE-I. OBJECTIVETo evaluate the factors and 30-day mortality risks associated with the postoperative nonresumption of an ACE-I. DESIGNA retrospective cohort study. SETTINGVeterans Affairs (VA) Healthcare System. PATIENTSA total of 294,505 admissions in 240,978 patients with multiple preoperative prescription refills (>3) for an ACE-I who underwent inpatient surgery from calendar years 1999 to 2012. INTERVENTIONNone. MEASUREMENTSWe classified surgical admissions based upon the timing of postoperative resumption of an ACE-I prescription from the day of surgery through postoperative days 0 to 14 and 15 to 30, and collected 30-day mortality data. We evaluated the relationship between 30-day mortality and the nonresumption of an ACE-I from postoperative day 0 to 14 using proportional hazard regression models, adjusting for patient- and hospital-level risk factors. Sensitivity analyses were conducted using more homogeneous subpopulations and propensity score models. RESULTSTwenty-five percent of our cohort did not resume an ACE-I during the 14 days following surgery. Nonresumption of an ACE-I within postoperative day 0 to 14 was independently associated with increased 30-day mortality (hazard ratio: 3.44; 95% confidence interval: 3.30-3.60; P<0.001) compared to the restart group. Sensitivity analyses maintained this relationship. CONCLUSIONSNonresumption of an ACE-I is common after major inpatient surgery in the large VA Health Care System. Restarting of an ACE-I within postoperative day 0 to 14 is, however, associated with decreased 30-day mortality. Careful attention to the issue of timely reinstitution of chronic medications such as an ACE-I is indicated. Journal of Hospital Medicine 2014;9:289-296. 2014 Society of Hospital Medicine
引用
收藏
页码:289 / 296
页数:8
相关论文
共 40 条
  • [1] A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality
    Austin, Peter C.
    [J]. MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) : 119 - 151
  • [2] Association of ICU or Hospital Admission With Unintentional Discontinuation of Medications for Chronic Diseases
    Bell, Chaim M.
    Brener, Stacey S.
    Gunraj, Nadia
    Huo, Cindy
    Bierman, Arlene S.
    Scales, Damon C.
    Bajcar, Jana
    Zwarenstein, Merrick
    Urbach, David R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (08): : 840 - 847
  • [3] Potentially unintended discontinuation of long-term medication use after elective surgical procedures
    Bell, Chaim M.
    Bajcar, Jana
    Bierman, Arlene S.
    Li, Ping
    Mamdani, Muhammad M.
    Urbach, David R.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (22) : 2525 - 2531
  • [4] The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials
    Brugts, Jasper J.
    Ninomiya, Toshiharu
    Boersma, Eric
    Remme, Willem J.
    Bertrand, Michel
    Ferrari, Roberto
    Fox, Kim
    MacMahon, Stephen
    Chalmers, John
    Simoons, Maarten L.
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (11) : 1385 - 1394
  • [5] Guidelines for the management of chronic medication in the perioperative period: systematic review and formal consensus
    Castanheira, L.
    Fresco, P.
    Macedo, A. F.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (04) : 446 - 467
  • [6] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [7] Angiotensin system inhibitors in a general surgical population
    Comfere, T
    Sprung, J
    Kumar, MM
    Draper, M
    Wilson, DP
    Williams, BA
    Danielson, DR
    Liedl, L
    Warner, DO
    [J]. ANESTHESIA AND ANALGESIA, 2005, 100 (03) : 636 - 644
  • [8] STOPPING AND RESTARTING MEDICATIONS IN THE PERIOPERATIVE PERIOD
    CYGAN, R
    WAITZKIN, H
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1987, 2 (04) : 270 - 283
  • [9] Patterns of Use of Perioperative Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass Effects on In-Hospital Morbidity and Mortality
    Drenger, Benjamin
    Fontes, Manuel L.
    Miao, Yinghui
    Mathew, Joseph P.
    Gozal, Yaacov
    Aronson, Solomon
    Dietzel, Cynthia
    Mangano, Dennis T.
    [J]. CIRCULATION, 2012, 126 (03) : 261 - +
  • [10] Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events
    Enseleit, F
    Hürlimann, D
    Lüscher, TF
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 : S21 - S30